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Objective: The objective was to assess mitral valve replacement in a minimally 
invasive fashion by means of port-access technology. Methods: Fifteen dogs, 28 -- 3 
kg (mean -+ standard deviation), were studied with the port-access mitral valve 
replacement system (Heartport, Inc., Redwood City, Calif.). Eleven dogs under- 
went acute studies and were sacrificed immediately after the procedure. Four dogs 
were allowed to recover and then were sacrificed 4 weeks after operation. 
Cardiopulmonary bypass was conducted by femoral calmulation with an endovas- 
cular balloon catheter for aortic occlusion, root venting, and antegrade delivery of 
eardioplegic solution. Catheters were inserted in the jugular vein for pulmonary 
artery venting and retrograde delivery of cardioplegic solution. Through the oval 
port, a prosthesis (St. Jude Medical, Inc., St. Paul, Minn., or CarboMedics, Inc., 
Austin, Texas) was inserted through the left atrial appendage and secured to the 
anulus with sutures. Deairing was performed. Results: Cardiopulmonary bypass 
duration was 114 - 24 minutes and aortic crossdamp time was 68 -+ 14 minutes. 
All animals were weaned from cardiopulmonary bypass in sinus rhythm. Cardiac 
output and pulmonary artery occlusion pressure were unchanged (2.8 -+ 0.7 L/min 
and 7 -- 3 mm Hg before operation vs 2.6 -+ 0.6 L/min and 9 -+ 4 mm Hg after 
operation). There was no mitral regurgitation according to left ventriculography in
13 of 15 dogs. In two dogs there was interference with prosthetic valve closure by 
residual native anterior leaflet tissue. Pathologic examination otherwise showed 
normal healing without perivalvular discontinuity. Microscopic studies showed no 
damage to the valve surfaces. Transthoracic echocardiography of the four dogs in 
the long-term study showed normal ventricular and prosthetic valve function 4 
weeks after the operation. Conclusion: Mitral valve replacement with a minimally 
invasive method has been demonstrated in dogs. A clinical trial is in progress. 
(J Thorac Cardiovasc Surg 1996;112:1268-74) 
D uring the last few years, there has been signif- icant development in the area of video-as- 
sisted surgical procedures. 1 Important advances 
have been achieved in the diagnosis and treatment 
of diseases of the chest in a minimally invasive 
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fashion. 2 The application of this technique to 
cardiac surgical procedures, however, has been 
rather slow. The inability to provide cardiopulmo- 
nary support and myocardial protection without 
performing a median sternotomy or gross thora- 
cotomy has represented a significant hurdle, lim- 
iting the implementation of such new technologies 
in cardiac surgery. 
The surgical management of mitral valve disease 
has been well established since the early 1960s. 
Replacement of the mitral valve with a mechanical 
prosthesis was first performed in 1960 by Starr and 
Edwards9 Subsequent refinements and progress in 
the materials and design of valvular prosthesis have 
led to continuous improvement in the results of 
surgical therapy of mitral valve disease. 4-6 
On the basis of these preliminary considerations, 
we developed a procedure called "port-access mitral 
valve replacement." Our procedure allows establish- 
ment of full cardiopulmonary bypass (CPB), car- 
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Fig. 1. Diagram of oval port and thoracoscope. 
dioplegic arrest of the heart, and myocardial protec- 
tion without gross opening of the chest. This study 
was aimed at evaluating in the canine model a 
minimally invasive system for replacement of the 
mitral valve. 
Methods 
The port-access mitral valve replacement procedure 
was performed in 15 dogs (28 + 3 kg, mean -+ standard 
deviation). Eleven dogs were studied during the acute 
phase and sacrificed after the study. Four dogs were 
allowed to recover and humanely killed after 4 weeks. The 
dog was selected for the experimental model because of 
the similarity of its cardiac anatomy to that of human 
beings. 
All animals received humane care in accordance with 
the "Principles of Laboratory Animal Care" formulated 
by the National Society for Medical Research and the 
"Guide for the Care and Use of Laboratory Animals" 
prepared by the Institute of Laboratory Animal Resources 
and published by the National Institutes of Health (NIH 
publication No. 86-23, revised 1985). 
Anesthesia was induced with 10 mg/kg tiletamine- 
zolazepam (Telazol) and maintained with intravenous 
pentobarbital nd inhaled isoflurane. All dogs were me- 
chanically ventilated with 100% oxygen through an endo- 
tracheal tube. Single-lung ventilation was obtained with a 
bronchial blocker (Meditech; Boston Scientific Corp., 
Watertown, Mass.) placed in the left main bronchus with 
the aid of bronchoscopy. 
The monitoring system consisted of a 7F thermodilution 
pulmonary artery catheter (Arrow International, Reading, 
Pa.) placed through a 10F venous heath in the jugular vein. 
Baseline cardiac output (CO) and pulmonary artery occlu- 
sion pressure were measured. Central venous pressure was 
monitored off the side arm of the sheath. An arterial line was 
placed in the carotid artery, and electrocardiograms and 
rectal temperatures were also monitored. 
All four long-term survival studies were performed 
under sterile techniques. All four dogs received intrave- 
nously a preoperative dose of 30 mg/kg cephalexin. 
Fig. 2. Diagram of surgical instruments passed through 
oval port. 
Access to the heart was gained through a 35 × 17 mm 
oval port (Heartport, Inc., Redwood City, Calif.) placed in 
the fifth intercostal space between the midaxillary and 
posterior axillary lines. An additional 10 mm port was 
created in the fourth intercostal space for insertion of an 
articulating thoracoscope (Distalvu 360; Welch Allyn, 
Inc., Skaneateles Falls, N.Y.), as shown in Fig. 1. After 
deflation of the left lung, the pericardium was opened 
longitudinally anterior to the phrenic nerve with specifi- 
cally designed instruments passed through the oval port 
(Fig. 2). During the surgical procedure, all the instruments 
were passed through the oval port. These specifically 
designed instruments are shown in Fig. 3. The atrial 
appendage was then suspended from the left anterior 
chest wall by means of temporary clips (Advanced Surgi- 
cal, Inc., Princeton, N.J.). A myocardial temperature 
probe was also inserted in the left ventricular free wall 
(Mon-a-therm Myocardial; Mallinckrodt Medical, Inc., St. 
Louis, Mo.; Fig. 4). 
After systemic heparinization with 300 U/kg intrave- 
nous heparin, a 9.5F endovascular pulmonary artery vent 
catheter (Endopulmonary Vent; Heartport) was inserted 
in place of the thermodilution pulmonary artery catheter 
and an 8.5F coronary sinus cardioplegia catheter (Endo- 
sinus Catheter; Heartport) was positioned in the coronary 
sinus through a jugular vein under fluoroscopic guidance. 
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Fig. 3. Surgical instruments and valve with sizer. 
Fig. 4. Exposure of left atrial appendage through oval 
port. 
The right femoral artery and vein, previously exposed, 
were cannulated with 14F and 17F cannulas, respectively 
(DLP, Inc., Grand Rapids, Mich.). The tip of the venous 
cannula was situated at the superior cavoatrial junction 
under fluoroscopic guidance. A 12F endovascular three- 
lumen balloon-tipped catheter (Endoaortic Clamp; 
Heartport) was introduced through the left femoral ar- 
tery, and its tip was positioned in the ascending aorta 
under fluoroscopic guidance. The distal end of the en- 
doaortic clamp was then connected to the balloon-infla- 
tion and aortic root pressure-monitoring lines, as well as 
to the cardioplegia and venting lines. 
The arterial and venous lines were connected and CPB 
was instituted with systemic hypothermia between 20 ° and 
25 ° C. A centrifugal pump with a remote driver (Sarns 
8000; Sarns, 3M Health Care, Ann Arbor, Mich.) was used 
tO augment venous drainage. 
Under fluoroscopic guidance, the balloon was inflated 
and cold, high-potassium blood cardioplegic solution (20 
ml/kg) was delivered in an antegrade fashion, maintaining 
an aortic root pressure between 50 and 70 mm Hg. After 
cardioplegic nfusion and with the heart in diastolic arrest, 
the position of the Endovascular clamp was again checked 
fluoroscopically. 
Cardioplegic solution was infused until a myocardial 
temperature of less than 15°C was achieved. Subse- 
quently, it was infused at a dose of 10 ml/kg in a 
retrograde manner through the coronary sinus catheter 
(Endosinus Catheter; Heartport; Fig. 5) every 20 minutes 
or in the presence of any electrical activity. 
The left atrial appendage was opened vertically, and 
with the aid of retraction suture the mitral valve was 
visualized irectly and videothoracoscopically. Theanulus 
was sized and sutures were inserted into it by means Of 
specifically designed instruments. In all animals, the native 
valve was left in situ. The sutures were organized around 
the 0val port (Fig. 6). These sutures were then passed 
through the sewing ring of the appropriately sized mitral 
valve prosthesis (St. Jude Medical, Inc., St. Paul, Minn.; or 
CarboMedics, Inc., Austin, Texas), which was then seated 
on the anulus of the mitral valve (Fig. 7). The sutures were 
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Fig. 6. Sutures passed through mitral valve anulus. 
Fig. 5. Schematic diagram of endovascular CPB system. 
tied, creating the knot outside the chest wall and sliding it 
with a knot pusher onto he sewing ring. The sutures were 
then cut and the valve leaflet motion was tested with a 
soft-tip probe (Fig. 8). Removal of any noncoronary 
collateral blood returning to the surgical field was accom- 
plished with a cardiotomy aspirator passed through the 
oval port as necessary. 
Rewarming was started while the atriotomy was being 
closed with 4-0 Prolene suture (Ethicon, Inc., Somerville, 
N.J.). Deairing was accomplished by turning off the pul- 
monary and aortic root venting lines, inflating the lungs to 
displace air from the pulmonary veins, and adding volume 
from the venous reservoir. After closure of the atrium 
during a Valsalva maneuver, the dog was placed in a 
reverse Trendelenburg position and the aortic root and 
pulmonary vents were reopened. No intraoperative echo- 
cardiography was performed. Subsequently, with the dog 
in Trendelenburg position, the endoaortic balloon clamp 
was deflated under fluoroscopic guidance. External or 
internal defibrillation was performed if necessary. The 
dog was rewarmed to 37 ° C, weaned from CPB, and had 
all the cannulas removed. In the long-term (survival) 
group animals, a 22F chest tube was placed in the left 
pleural cavity and connected to a Heimlich valve. Heparin 
was reversed with protamine (1 mg/100 U heparin). 
The thermodilution catheter was reintroduced, volume 
replenishment was carried out to achieve a pulmonary 
artery occlusion pressure similar to preoperative values, 
and CO was measured. Left ventriculography was then 
Performed. 
The acute study animals were sacrificed immediately 
after operation, whereas the long-term study animals were 
maintained on 30 mg/kg intramuscular cephalothin (Kef- 
lin) twice daily for 48 hours, followed by 35 mg/kg oral 
cephalexin twice daily for 7 days, and anticoagulated with 
1 mg/kg subcutaneous heparin, oral warfarin, and approx- 
imately 80 mg oral aspirin daily. Prothrombin times were 
measured daily for 1 week and then weekly for the 
duration of the study. Warfarin was adjusted to keep the 
prothrombin time at three times the baseline value. 
Before the animals were sacrificed, transthoracic echocar- 
diography was performed. 
After the animals were heparinized and humanely 
killed, the hearts were removed. The valves were ex- 
planted, rinsed in distilled water, soaked in 2% trypsin to 
remove any debris, and subsequently examined by light 
microscopy (×25) to assess the presence of any damage. 
In addition, samples of myocardium, aorta, kidneys, liver, 
spleen, bowel, and hind limb muscles were taken for 
histologic examination. 
Statistical analysis was performed with paired t tests. A 
p value less than 0.05 was considered significant. 
Results 
All 15 dogs survived the operation. In all 15 
studies, excellent visualization of the mitral valve 
was obtained directly through the oval port and with 
video-assisted thoracoseopy. 
Eleven of the 15 prostheses were St. Jude Medical 
valves, ranging from 19 to 23 mm in size, and four 
were 18 mm CarboMedics valves. All dogs were 
successfully maintained on CPB for 114 _+ 24 min- 
utes (mean _+ standard deviation). Aortic cross- 
clamp time was 68 _+ 14 minutes (mean _+ standard 
deviation). Kinetically assisted venous drainage re- 
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Fig. 8. Prosthesis sutured in place. 
Fig. 7. Mechanical prosthesis being passed through oval 
port. 
sulted in a venous line pressure of -40 to -80 mm 
Hg during CPB. Endopulmonary vent flows gener- 
ally remained below 20 ml/min during this time, with 
satisfactory cardiac decompression. 
The position of the endoaortic clamp was checked 
before deflation in three of the four long-term 
studies. No migration was observed. In one animal, 
the balloon of the endoaortic clamp deflated twice 
spontaneously and had to be replaced, without 
untoward effects. In all 15 animals, there was no 
clinical, radiographic, or postmortem evidence of 
aortic insufficiency or aortic valve damage. 
At the completion of the surgical procedure, the 
endoaortic clamp was successfully deflated and the 
animals were resuscitated to sinus rhythm and 
weaned from CPB without inotropic support. Pre- 
operative and postoperative CO measurements 
were obtained: the mean preoperative CO was 2.8 _+ 
0.7 L/min, with pulmonary artery occlusion pressure 
of 7 _+ 4 mm Hg. The postoperative alues were not 
significantly different at 2.6 _ 0.6 L/rain and 9.0 _+ 4 
mm Hg, respectively. 
There was minimal entrapment of the anterior 
leaflet into the closing mechanism of the prosthesis 
in two of the early acute study animals. This pro- 
duced mild to moderate regurgitation on left ven- 
triculography. 
Three of the four dogs in the survival study were 
anticoagulated uneventfully. One dog had upper 
gastrointestinal bleed necessitating transfusion. 
Four weeks after operation, before they were killed, 
all four dogs underwent transthoracic e hocardiog- 
raphy. This revealed normal right and left ventricu- 
lar function, no aortic regurgitation, and excellent 
function of the mitral prosthesis. Light microscopic 
examination (25 ×) of the mitral prosthesis was also 
performed and revealed no evidence of damage. 
Postmortem examination of the heart demonstrated 
normal healing of the valve. Examined of other 
organs did not reveal any pathologic hanges. 
Discussion 
The goal of this study was to evaluate the feasi- 
bility of replacing the mitral valve in a minimally 
invasive fashion. The application of these tech- 
niques to cardiac surgery has historically been ham- 
pered by the inability to provide adequate myocar- 
dial protection and cardiopulmonary support] The 
introduction of our novel method of endovascular 
myocardial protection allows the establishment of a 
quiet, bloodless urgical field, with the heart opti- 
mally protected and decompressed and with ade- 
quate systemic support provided by CPB. 8 
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The preoperative and postoperative CO measure- 
ments in the presence of comparable preloading 
conditions demonstrate that excellent myocardial 
preservation can be accomplished with this method. 
A more detailed assessment of myocardial preser- 
vation achieved with the endovascular CPB system, 
as opposed to the standard open-chest ystem, was 
performed by Schwartz and colleagues. 9 They found 
no significant differences. Furthermore, the endo- 
vascular CPB system was previously used in "port- 
access coronary artery bypass grafting," achieving 
the same excellent results in terms of myocardial 
protection and preservation of end-organ func- 
tion.lO, n In our study, the ability to adequately 
visualize the mitral valve was also tested. Superb 
exposure of the valve and its apparatus was accom- 
plished by direct visualization through the oval port 
and by video-assisted thoracoscopy. 
The insertion of the oval port did not require rib 
spreading or gross thoracotomy. This technique thus 
introduces the possibility of reduced chest discom- 
fort during postoperative r covery. I2 Despite the 
presence of a normally sized left atrium, it was 
possible to easily manipulate the anatomic struc- 
tures of interest by means of specifically designed 
instruments, without any resultant damage to the 
mechanical prosthesis according to microscopic ex- 
amination. Entrapment of valve tissue into the 
closing mechanism ofthe mechanical prosthesis was 
encountered in two of the first acute animal studies, 
but this was probably related to initial inexperience. 
During the last decade, modern surgical treat- 
ment of mitral valve diseases has expanded rapidly 
into a wide array of reconstructive procedures and 
percutaneous interventions. 13-16 Replacement ofthe 
mitral valve remains a well-established treatment 
modality, however, accompanied by very low mor- 
bidity and mortality. Iv Several approaches have 
been used for its performance, including median 
sternotomy, right thoracotomy, and left thoracoto- 
my. 18 
The recent development of video-assisted thora- 
coscopy has resulted in significant advances in the 
management of chest diseases, mainly as a result of 
the ability to visualize the anatomic structures of 
interest with excellent resolution and of the devel- 
opment of specifically designed instruments that 
allow surgical maneuvers to be performed from 
outside the chest cage. The field of cardiac surgery 
has not enjoyed similar progress, however, because 
of the inability to arrest and protect he heart while 
maintaining end-organ function. The endovascular 
support and cardioplegic system we report here 
allowed us to obtain optimal visualization of the 
mitral valve and its subvalvular apparatus and to 
perform a technically satisfactory and uneventful 
implantation ofa mechanical prosthesis. Because of 
the excellent exposure, it is reasonable to infer that 
more complex resection, decalcification, and recon- 
struction of the mitral valve and its apparatus would 
be feasible. 
There are several limitations to the model and the 
study design. The canine aorta is remarkably shorter 
than the human aorta, limiting the area available for 
inflation of the endovascular clamp. However, no 
injuries to valvular or vascular structures were cre- 
ated. Although the absence of atherosclerosis pre- 
vents us from fully assessing the possibility of aortic 
injury, it seems theoretically possible to decrease 
atheroembolization associated with aortic cannula- 
tion and external crossclamping. 19 
The anatomic configuration ofthe dog's chest was 
another significant limitation of our model. The 
heart is closer to the lateral chest wall in dogs than 
in human beings because the major axial diameter of 
the canine chest cage is the anteroposterior. This 
feature in turn allows an easier and closer approach 
to the mitral valve than would be possible in human 
beings. Also, the presence of a normal valve and 
apparatus without annular calcification significantly 
simplified the operation. Deairing of cardiac ham- 
bers performed according to standard maneuvers 
appeared to be adequate, as indicated by the ab- 
sence of neurologic deficits in the four long-term 
study dogs. 2°' 21 Finally, this was not a controlled, 
randomized study: our goal was to study the feasi- 
bility, safety, and efficacy of this new technology. 
On the basis of these data, we conclude that it is 
possible to perform a replacement of the mitral 
valve with a mechanical prosthesis through small 
thoracic ports in an animal model. Applied to 
human beings, this minimally invasive approach as 
the potential to decrease postoperative discomfort, 
morbidity, and overall cost, and to expedite the 
return to gainful activity, while still providing the 
benefits of a well-established therapeutic modality. 
A clinical trial of this method is in progress. 
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Discussion 
Dr. Randall B. Griepp (New York, N.Y.). With respect 
to your conclusion that a clinical trial is appropriate, the 
mitral valve is a little further from the chest wall in people 
than it is in dogs. Clinically, what incision do you propose, 
and do you have any idea how you are going to get the 
mitral valve close enough to be reached? 
Dr. Pompili. To surgically manipulate the mitral valve, 
we use specifically designed instruments. As far as the 
surgical approach in a human being is concerned--and 
there is actually a phase 1, FDA-approved clinical trial 
open at Stanford--we plan to approach the mitral valve 
from the right side of the chest through the fourth 
intercostal space with an incision that probably will be 
around 7 or 8 cm long, and we plan either to once again 
use the oval port or, if necessary, to resect a short segment 
of rib. The remaining steps of the operation would be 
substantially similar to what was shown in my presenta- 
tion. 
Dr. Peter Yong (Dallas, Tex.). I have just two questions 
for you. Can you share with us the technique of your 
deairing on the left side of the heart? In the animal model, 
when you place the animal in the lateral position, your 
access to the mitral valve is quite easy. In a human being, 
do you think that you can use the same technique and 
place sutures in a mitral valve replacement? The mitral 
valve is far away from the chest wall surface and less 
accessible. Could you share some of your insights with 
me? 
Dr. Pompili. In response to the first question, deairing 
in the dog was a little more laborious than we suspect it 
will be in human beings. The dog was initially placed in a 
reverse Trendelenburg position, while the aortic root vent, 
which is provided through the same catheter as the 
balloon for inflation for the clamp, is working. Volume is 
then added from the pump and the anesthesiologist 
performs some Valsalva maneuvers; subsequently, once 
the clamp is deflated, the dog is placed in the Trendelen- 
burg position and the same maneuvers are performed. 
As for your second question, we are actually submitting 
these data to the American Heart Association meeting. 
We have already performed four mitral valve replace- 
ments in human beings in which the approach was from 
the right side. You are absolutely correct in your anatomic 
remarks. From the right side, the mitral valve anulus is 
certainly more distant from the chest wall; from the left 
side, according to some cadaver studies that we have 
conducted, the mitral anulus is actually closer to the chest 
wall. However, from this initial preliminary clinical expe- 
rience, the distance between the chest wall and the anulus 
does not seem to be an overwhelming problem. Manipu- 
lation of the valve can be performed without difficulty with 
the specifically designed instruments. 
